跳至主要内容
临床试验/NCT05037032
NCT05037032已完成4 期

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

VA Loma Linda Health Care System1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2021年8月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
16
试验地点
1
主要终点
Groningen Sleep Quality Scale

研究概览

简要总结

Sleep at altitude is often poor. The purpose of this study is to evaluate the effects of a single dose of the opioid antagonist, naltrexone, on sleep quality and periodic breathing after rapid ascent to ~3800m altitude.

详细描述

Sleep at high altitude is notoriously poor due to a combination of the unusual sleep environment and hypoxia during sleep. Many people develop what is called periodic breathing (PB) during sleep. PB may improve overall mean nocturnal oxygen saturation (SpO2) although this is not entirely clear. Simultaneously, PB may further disturb sleep at altitude and has been associated with nighttime arousals from sleep. Medications that may decrease the amount of PB might improve sleep quality. The FDA approved drug, naltrexone, is a specific antagonist to the brain opioid receptors. It is a non-addicting drug which has never been studied at altitude.

Clinical Relationships: Sleep disordered breathing is a very common disorder throughout the population, but it worsens with increasing age and BMI. At the same time, many in our Veteran population live in the local mountains and undoubtedly develop PB during sleep in addition to having obstructive sleep apnea.

Objectives: The purpose to this study is to evaluate the effects of a single dose of naltrexone on PB and oxygen saturation during sleep at altitude in healthy young participants. The additional purpose will be to assess the subject-perceived sleep quality after the use of naltrexone vs. placebo.

Research Design: A prospective, randomized, double-blind, crossover study.

Methodology: We plan recruit up to 30 healthy study subjects with no history of sleep disordered breathing. Potential participants will be screened to ensure inclusion and exclusion criteria are met. A baseline low altitude sleep study will be preformed at home. No medication will be given before this baseline sleep study. The sleep study will be similar to the home sleep studies routinely used by the VA Loma Linda Healthcare System's Sleep Center. Participants will be transported for High Altitude Trip 1 to the Barcroft Laboratory at the White Mountain Research Center (WMRC) at 3810 m altitude. At WMRC they will have a sleep study performed, similar to the baseline sleep study, after taking either a single dose of naltrexone or matching placebo. After an appropriate washout period (at least 5 half-lives) subjects will again be studied (High Altitude Trip 2) taking the alternate medication (naltrexone/placebo) to the one used in the first study. Order of placebo vs. naltrexone will be randomized. Prior to sleep the subject will fill out questionnaires detailing how sleepy they are. On the morning following each sleep study, subjects will fill out a short questionnaire assessing the quality of their sleep.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Randomized double-blind, placebo controlled crossover trial

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy males or females
  • Age 18 to 35 years of age
  • Body-mass index (BMI) ≤ 27
  • At least two weeks after full vaccination for Sars-CoV-
  • Proof of vaccination will be determined by the investigators.

排除标准

  • Current smoker or significant past smoking history (≥ 10 pack-years)
  • History of COPD, interstitial lung disease or other pulmonary disease that in the opinion of the investigators would compromise the subject's safety at altitude
  • History of obstructive sleep apnea, or other history of sleep disordered breathing, or previous use of nighttime continuous positive airway pressure (CPAP)
  • Any history of chronic opioid use or prior abuse history
  • Any history of alcohol abuse
  • Use of any opioid substance (prescribed or otherwise) within 2-weeks of study enrollment
  • Any medications that might, in the opinion of the investigators, interfere with or alter respiratory control, (e.g. acetazolamide). Use of oral contraceptive medications would be allowed as long as the study subject is on the same agent/dose during both arms of the study.
  • Recent (within 3 weeks) exposure to altitudes ≥ 3,500 m at time of 1st altitude trip

研究组 & 干预措施

Study drug naltrexone hydrochloride

Active Comparator

50 mg Naltrexone PO

干预措施: Naltrexone Pill (Drug)

Matching placebo for naltrexone hydrochloride

Placebo Comparator

Matching placebo for Study Drug Naltrexone

干预措施: Placebo (Drug)

结局指标

主要结局

Groningen Sleep Quality Scale

时间窗: Up to 60 days

Assessment to understand sleep quality (0 = good sleep, maximum score of 14 points indicates poor sleep the night before)

Nighttime oxygen saturation

时间窗: Up to 60 days

Change from baseline in nighttime SpO2

Periodic Breathing

时间窗: Up to 60 days

Change from baseline in portion of night spent with periodic breathing

Epworth Sleepiness Scale

时间窗: Up to 60 days

Subjective measurement of one's daytime sleepiness (0 = less sleepy, 24= excessively sleepy)

Stanford Sleepiness Scale

时间窗: Up to 60 days

Self-reported assessments of how alert one is currently feeling (1= wide awake, X=asleep)

次要结局

未报告次要终点

研究者

发起方
VA Loma Linda Health Care System
申办方类型
Fed
责任方
Principal Investigator
主要研究者

James D. Anholm, M.D.

Staff physician; Pulmonary & Critical Care

VA Loma Linda Health Care System

研究点 (1)

Loading locations...

相似试验

Effects of Naltrexone on Nocturnal Breathing... | 临床试验